CN1304366C - N－(反式－4－异丙基环己基羰基)－d－苯丙氨酸的晶形 - Google Patents

N－(反式－4－异丙基环己基羰基)－d－苯丙氨酸的晶形 Download PDF

Info

Publication number
CN1304366C
CN1304366C CNB038084368A CN03808436A CN1304366C CN 1304366 C CN1304366 C CN 1304366C CN B038084368 A CNB038084368 A CN B038084368A CN 03808436 A CN03808436 A CN 03808436A CN 1304366 C CN1304366 C CN 1304366C
Authority
CN
China
Prior art keywords
nateglinide
solvent
solution
crystalline form
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038084368A
Other languages
English (en)
Chinese (zh)
Other versions
CN1646481A (zh
Inventor
P·A·萨顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1646481A publication Critical patent/CN1646481A/zh
Application granted granted Critical
Publication of CN1304366C publication Critical patent/CN1304366C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB038084368A 2002-04-15 2003-04-14 N－(反式－4－异丙基环己基羰基)－d－苯丙氨酸的晶形 Expired - Lifetime CN1304366C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37262502P 2002-04-15 2002-04-15
US60/372,625 2002-04-15

Publications (2)

Publication Number Publication Date
CN1646481A CN1646481A (zh) 2005-07-27
CN1304366C true CN1304366C (zh) 2007-03-14

Family

ID=29250881

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038084368A Expired - Lifetime CN1304366C (zh) 2002-04-15 2003-04-14 N－(反式－4－异丙基环己基羰基)－d－苯丙氨酸的晶形

Country Status (8)

Country Link
US (3) US7247746B2 (enExample)
EP (1) EP1497258A1 (enExample)
JP (2) JP4615866B2 (enExample)
CN (1) CN1304366C (enExample)
AU (1) AU2003242520A1 (enExample)
BR (1) BR0309210A (enExample)
CA (1) CA2482669A1 (enExample)
WO (1) WO2003087038A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109100430A (zh) * 2017-06-20 2018-12-28 珠海同益制药有限公司 一种那格列奈手性异构体色谱分析方法

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
WO2004020396A1 (en) * 2002-08-28 2004-03-11 Dr. Reddy's Laboratories Limited Crystalline form of nateglinide and process for preparation thereof
WO2004074330A1 (ja) * 2003-02-18 2004-09-02 Konishi Co., Ltd. 硬化性樹脂、その製造方法及び硬化性樹脂組成物
HU227073B1 (hu) * 2003-07-10 2010-06-28 Richter Gedeon Nyrt Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CN104350041A (zh) 2012-05-07 2015-02-11 塞利克斯比奥私人有限公司 用于治疗神经系统疾病的组合物和方法
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
CN104364230A (zh) * 2012-05-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗糖尿病的组合物和方法
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en) 2012-09-08 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
EP0526171B1 (en) * 1991-07-30 1997-03-05 Ajinomoto Co., Inc. Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them
EP1435912A4 (en) * 2001-09-12 2005-03-30 Alembic Ltd NOVEL STABLE CRYSTAL FORM OF N- (TRANS-4-ISOPROPYLCYCLOHEXYL CARBONYL) -D-PHENYLALANINE AND PREPARATION METHOD THEREOF
EP2264004A1 (en) * 2002-04-15 2010-12-22 Ajinomoto Co., Inc. New nateglinide crystals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109100430A (zh) * 2017-06-20 2018-12-28 珠海同益制药有限公司 一种那格列奈手性异构体色谱分析方法

Also Published As

Publication number Publication date
US20080081927A1 (en) 2008-04-03
BR0309210A (pt) 2005-02-09
US7247746B2 (en) 2007-07-24
US20080319222A1 (en) 2008-12-25
WO2003087038A1 (en) 2003-10-23
CA2482669A1 (en) 2003-10-23
JP2005522503A (ja) 2005-07-28
JP4615866B2 (ja) 2011-01-19
EP1497258A1 (en) 2005-01-19
CN1646481A (zh) 2005-07-27
AU2003242520A1 (en) 2003-10-27
JP2010265295A (ja) 2010-11-25
US20050256336A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
CN1304366C (zh) N－(反式－4－异丙基环己基羰基)－d－苯丙氨酸的晶形
EP0526171B1 (en) Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them
US5463116A (en) Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
JP5832716B2 (ja) ラキニモドナトリウムの結晶，及びその製造方法
CN100406436C (zh) 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
JP2010090174A (ja) 新規ナテグリニド結晶
CN105481952B (zh) 一种含氮杂环六肽前体的组合物及其制备方法和用途
WO2018015974A1 (en) Polymorphic forms and amorphous solid dispersion of selexipag
WO2023181075A1 (en) Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
KR20230117408A (ko) 2-하이드록시-5-[2-(4-(트리플루오로메틸페닐)에틸아미노)]벤조산결정형 및 이의 제조 방법
EP1844017A1 (en) An amorphous and three crystalline forms of rimonabant hydrochloride
CN109988074A (zh) 一种适合药用的硫酸特布他林晶型b的制备方法
CN105992769A (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
JP2008534578A (ja) ラベプラゾールナトリウムの改良された製法
JP7356176B2 (ja) トレプロスチニル一水和物結晶およびその製造方法
JP3001975B2 (ja) 結晶性チアガビン塩酸塩−水和物、その製造方法および用途
EP4161912A1 (en) Preparation of highly pure amorphous dapagliflozin
WO2017071375A1 (zh) 一种氘代咪唑酮化合物的晶型及其制备方法和用途
WO2023158772A1 (en) Solid state forms of danicopan and process thereof
JP2002531452A (ja) 混合パロキセチンプロパン−２−オール溶媒和物
WO2009063476A1 (en) A crystalline form of atorvastatin hemi magnesium salt and a process thereof
JPS6040414B2 (ja) セクレチンの抽出方法
EP1551853A1 (en) Method for the separation of triglycoalkaloids

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Basel, Switzerland

Patentee before: Novartis AG

CX01 Expiry of patent term

Granted publication date: 20070314

CX01 Expiry of patent term